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The proinflammatory cytokine tumor necrosis factor-alpha (TNF-a) inhibits normal keratinocytes proliferation. However, many human
papillomavirus (HPV)-immortalized or transformed cell lines are resistant to TNF-a antiproliferative effect. The present study analyzes the
effects of TNF-a on organotypic cultures of primary human keratinocytes (PHKs) that express HPV-18 oncogenes. Raft cultures prepared
with PHKs acutely transfected with HPV-18 whole genome or infected with recombinant retroviruses containing only E6/E7 or E7 were
treated with 2 nM TNF-a. While BrdU incorporation into basal/parabasal cells of normal PHKs cultures was markedly inhibited by TNF-a
cultures transfected with HPV-18 whole genome showed proliferation in all cell strata. Furthermore, BrdU incorporation into cultures
expressing E6/E7 or E7 was not significantly reduced, indicating that E7 alone confers partial resistance to TNF-a. Besides, TNF-a treatment
did not alter p16ink4a, p21cip1, p27kip1, or cyclin E levels, but did reduce cyclin A and PCNA levels in sensitive cells.
D 2004 Elsevier Inc. All rights reserved.
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Human papillomaviruses (HPVs) are small DNA viruses
that show a high degree of tropism for cutaneous andmucosal
squamous epithelial cells. Individual HPV types display
specificities for both the anatomic site and the histopathology
of the associated lesions. Mucosal HPVs preferentially infect
the genital tract, causing warts and condylomas that usually
regress. Such infections are common in sexually active
individuals. However, a small percentage of women who are0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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Uruguay.persistently infected with oncogenic genotypes, such as HPV-
16, -18, -31, or -33, develop high-grade dysplasias and
cervical cancer (Bosch et al., 2002; Ho et al., 1995; Kadish et
al., 1997; Remmink et al., 1995; Schlecht et al., 2001). In
productive infections, the viral DNA replicate as extrachro-
mosomal plasmids in differentiated keratinocytes in which S
phase is reactivated by the viral oncogene E7. In contrast, in
malignant lesions, the oncogenic HPV genome frequently
integrates into the host DNA, and E6 and E7 are expressed at
elevated levels in basal/parabasal cells relative to benign
lesions in which their expression is below the sensitivity of in
situ detection (Chow and Broker, 1997a).
The ability of E6 and E7 proteins to bind and induce the
degradation of p53 and pRb tumor suppressor proteins,
respectively, is not only critical for viral replication, but is
also central to the malignant potential of these viruses
(Mu¨nger and Howley, 2002). E6 and E7 genes of oncogenic
HPVs cooperate to immortalize human keratinocytes in04) 233–243
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of normal human keratinocytes with recombinant HPV
DNA of oncogenic types causes low-grade dysplasias when
inoculated into athymic mice (Woodworth et al., 1990) or
grown in organotypic raft cultures (McCance et al., 1988;
Steenbergen et al., 1998). The continuous expression of
these proteins is required for maintaining the transformed
phenotype, as repression of E6 and E7 in HeLa cells causes
the reactivation of p53 and pRb tumor suppressor pathways,
leading to either apoptosis or senescence (DeFilippis et al.,
2003; Francis et al., 2000; Goodwin and DiMaio, 2000).
The host immune surveillance plays an important role in
controlling HPV infections. In immunocompetent hosts,
viral infection causes the production and release of several
cytokines from macrophages, NK cells, lymphocytes,
fibroblasts, and keratinocytes. Many of these cytokines,
such as TNF-a, IL-1, interferon-a, -h, and -g, down-
regulate HPVearly gene expression and retard the growth of
cell lines harboring the viral genome (Kim et al., 2000a;
Kyo et al., 1994; Pao et al., 1995). Among them, TNF-a is
one of the main mediators of inflammation in the skin and
mucosa, the first barrier encountered by an epitheliotropic
virus. This cytokine binds to cell surface receptors, TNFR1
and TNFR2 (Tartaglia and Goeddel, 1992), that are
members of the TNF receptor superfamily (Smith et al.,
1994). Ligand binding induces receptor trimerization and
initiates various signaling pathways that lead to growth
arrest, cell proliferation, differentiation, or apoptosis
(Nagata, 1997). The response to TNF-a depends on the
specific ligand–receptor interaction, as well as the cell type
and microenvironment (Wallach et al., 1999). TNFR1
activation by TNF-a has been associated with signaling
pathways involved in antiviral activities, cytotoxicity,
activation of transcription factors, and cell death (Tartaglia
et al., 1993; Wong et al., 1992).
Several lines of evidence suggest that immune effector
mechanisms against HPV-infected cells may indeed include
direct or indirect participation of TNF-a. Apoptosis and
spontaneous regression of papillomas correlate with high
level of expression of this cytokine in infiltrating mono-
nuclear cells (Hagari et al., 1995). In vitro studies have
shown that TNF-a is a potent inhibitor of normal human
keratinocyte proliferation. In these cells, the cyclin-depend-
ent kinase inhibitor p21CIP1 is activated through nuclear
factor-nB (NF-nB) and is an important mediator of this
growth arrest response (Basile et al., 2003). On the other
hand, HPV-18 and SV40 immortalized keratinocytes as well
as HPV-16 or -18 transformed keratinocytes are resistant to
the antiproliferative effect of TNF-a (Vieira et al., 1996;
Villa et al., 1992). Moreover, transfection of HPV-16 E6 into
TNF-a sensitive mouse fibroblast LM cells protects them
from TNF-induced apoptosis (Duerksen-Hughes et al., 1999)
and HPV-16 E7 overcomes TNF-a-mediated growth arrest
and induction of differentiation in submerged cultures of
keratinocytes (Basile et al., 2001). It has been also observed
that E7 interferes with NF-nB activation upon treatment withTNF-a, and does so through attenuation of the InB kinase a
activity (IKKa) (Spitkovsky et al., 2002). Studies involving
nontumorigenic somatic-cell hybrids between the cervical
carcinoma-derived HPV-18 positive cell line HeLa and
normal human fibroblast have shown that treatment with
TNF-a down-regulates HPV gene transcription and induces
the MCP-1 (monocyte chemoattractant protein-1) factor.
Significantly, none of these effects was observed in
tumorigenic hybrids segregants (Finzer et al., 2000; Soto et
al., 1999, 2000). Thus, it seems that the acquisition of TNF-a
resistance may be critical to HPV pathogenesis.
The issue whether HPV oncogenes can confer TNF-a
resistance during squamous epithelial differentiation has not
been examined in detail. In the present study, we have
analyzed the effects of TNF-a on organotypic raft cultures
of low-passage primary human keratinocytes (PHKs) after
acute transduction with HPV-18 genome or HPV-18
oncogenes. The raft culture system faithfully recapitulate
the HPV–host interactions observed in vivo (Chow and
Broker, 1997b). Besides, it simulates an S phase environ-
ment in which the negative regulation of host DNA
replication is similar to that observed in productive
infections (Jian et al., 1998, 1999; Noya et al., 2001). Our
results show that HPV-18 E7 alone is able to confer at least
partial resistance to TNF-a arrest of S phase entry.
Furthermore, we show that whole genomic HPV18 DNA
confers almost complete resistance to this cytokine, indicat-
ing that a role by additional viral factors in acquiring TNF-a
resistance cannot be excluded. Immunofluorescence and
Western blot analysis indicate that the inhibitory effect of
TNF-a on PHKs does not involve an increase in the levels
of CDK inhibitors such as p16ink4a, p21cip1, or p27kip1, nor
an alteration in cyclin E levels. However, it reduced the
levels of cyclin A and proliferating cell nuclear antigen
(PCNA) in cells sensitive to TNF-a.Results
TNF-a differentially affects the histology of organotypic raft
cultures of normal keratinocytes and keratinocytes
expressing HPV genes
We compared the effects of TNF-a on normal raft cultures
of early passages PHKs and on those acutely transfected with
HPV-18 whole genome DNA or transduced with recombi-
nant retroviruses containing HPV-18 URR-E7 or HPV-18
URR-E6/E7. The cultures were either untreated or treated on
day 9 with 2 nM of TNF-a for 72 h and exposed to BrdU for
the last 12 h before harvest on day 12. When untreated,
normal raft cultures closely resembled normal epithelium in
vivo with morphologically distinct basal, spinous, granular,
and cornified layers. The cells tended to start to flatten at the
mid spinous strata (Fig. 1a). Untreated raft cultures that
contained HPV-18 genome, E6/E7 oncogenes, or E7 onco-
gene alone, were also fully differentiated with comparable
Fig. 1. Effect of TNF-a on the histology of epithelial raft cultures. On day 9, control (PHK), E7- or E6/E7-expressing, or raft cultures transfected with HPV-18
whole genome were treated with 2 nM TNF-a for 72 h (b,d,f,h) or left untreated (a,c,e,g). BrdU was added in the last 12 h. Raft cultures were harvested, fixed
in buffered formalin, embedded in paraffin, cut into 4-Am sections, and stained with hematoxylin and eosin.
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parabasal stratum as well, were thicker than the control
cultures. In particular, many spinous and granular cells
retained a large nucleus even when they reached the super-
ficial stratum, just before they terminally differentiated into
cornified squames (Figs. 1c,e,g).
After treatment with TNF-a, normal raft cultures
exhibited a flattened morphology in all cell layers (Fig.
1b). The HPV-containing raft cultures had a reduced
thickness relative to the untreated cultures, and they also
had a more flattened morphology, but primarily in the basal
keratinocytes. Again, many spinous and granular cells
retained a large nucleus. These morphological alterations
were consistently observed in all the raft cultures sections
analyzed (Figs. 1d,f,h).
HPV-18 E7 confers resistance to TNF-a inhibition of S
phase entry
We evaluated the effects of TNF-a on the proliferation of
PHKs in organotypic cultures by immunohistochemistry. Inthe normal raft cultures, only basal/parabasal cells were
positive for BrdU (Fig. 2a) and TNF-a markedly inhibited
the proliferation of these cells. This is evident from the
decrease in the number of cells in the basal layer that
incorporate BrdU (Fig. 2b).
Previous studies have demonstrated that HPV16 or
HPV18 E7 alone induces host DNA synthesis in a fraction
of otherwise nonproliferating, differentiated keratinocytes
(Cheng et al., 1995; Flores et al., 2000; Jones et al., 1997;
Ruesch and Laimins, 1997). In the present study, BrdU-
positive cells were observed in a subset of cells at all strata
of raft cultures derived from PHKs transfected with the
complete HPV18 genome or transduced with URR-E6/E7 or
URR-E7 (Figs. 2c,e,g). Upon treatment with TNF-a, BrdU
incorporation was reduced in cultures derived from normal
PHKs (Fig. 2b), while it remained unaltered in cultures
containing HPV18 whole genome (Fig. 2h). In the supra-
basal strata, BrdU-positive nuclei were usually enlarged
relative to BrdU-negative cells, in agreement with endor-
eduplication and polyploidy (Chien et al., 2002). Besides, in
the E6/E7 and E7 cultures, the number of BrdU-positive
Fig. 2. Cellular DNA synthesis in raft cultures in the presence or absence of TNF-a. Raft cultures were the same as in Fig. 1. BrdU incorporation was detected
by immunohistochemical probing. To reveal tissue histology, sections were counterstained with hematoxylin.
Fig. 3. BrdU incorporation in raft cultures expressing HPV-18 genes is not
affected by TNF-a. The BrdU-positive/total nuclei ratio was determined by
direct counting cell nuclei under the microscope in three independent fields
of untreated (light gray) or TNF-a treated (dark gray) raft culture sections
(from the rafts shown in Fig. 1). The bars correspond to values obtained in
at least two different experiments.
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To quantify TNF-a effect on BrdU incorporation, the BrdU-
marked/total nuclei ratio was determined by direct counting
of BrdU-positive and -negative nuclei in all control and
TNF-a treated cultures. These results are summarized in
Fig. 3 and suggest that E7 expression alone is sufficient to
partially overcome the sensitivity to TNF-a.
Expression of genes involved in cell cycle regulation
To identify molecular events that could explain the
different responses of these raft cultures to TNF-a,
expression of p21cip1 and p27kip1 proteins was examined
along with BrdU incorporation by double immunofluor-
escence. p21cip1 and p27kip1 bind and inhibit cyclin E/cdk2
and cyclin A/cdk2, thereby preventing cells from entering
the S phase (Sherr and Roberts, 1999). In agreement with
our previous studies (Chien et al., 2002; Jian et al., 1998;
Noya et al., 2001), no p21cip1 protein was detected in raft
cultures of normal keratinocytes (Fig. 4a), nor in those
Fig. 4. Effect of TNF-a on p21cip1 protein accumulation and distribution in raft cultures. Double immunofluorescence assay to reveal cells positive for p21cip1
(Texas Red) and for BrdU (fluorescein, green) in sections of raft cultures described in Fig. 1.
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et al., 1998). In contrast, raft cultures of keratinocytes
transduced with HPV-18 URR-E7 or URR-E6/E7 or those
transfected with the entire HPV-18 genome presented a clear
induction of this protein in a subset of suprabasal cells (Figs.
4c,e,g). Interestingly, neither the signal intensity nor the
distribution pattern of the p21cip1 protein seemed to be
altered by treatment with TNF-a in any of the organotypic
cultures, suggesting that this CKI is not involved in the
effects caused by this cytokine (Figs. 4b,d,f,h). Expression
of p27kip1 was detected in some of the suprabasal layers of
raft cultures from both normal keratinocytes and those
expressing HPV-18 E7 gene. The same is observed in HPV
warty lesions (Chien et al., 2002; Noya et al., 2001). The
distribution of p27kip1 was also mutually exclusive with that
of BrdU incorporation as previously described (Figs.
5a,c,e,g). The signal levels and distribution of this protein
were not altered by TNF-a, indicating that the effects of this
cytokine are also independent of p27kip1 (Figs. 5b,d,f,h).For more quantitative information, we performed West-
ern blot analysis using whole cell extracts of raft cultures for
these two CKIs. The results are consistent with the in situ
analyses as we detected little or no difference in raft culture
with or without TNF-a treatment (Fig. 6a). We then
examined by Western blot the effects of TNF-a on the
expression of other cell cycle regulatory proteins, including
cyclin E, cyclin A, proliferating cell nuclear antigen
(PCNA), and p16ink4a.
Cyclin E is required for S phase entry and is usually
below detection by in situ methods in normal raft
cultures but its level is abnormally high in E7-expressing,
differentiated cells. This is because cyclin E/cdk2 is
stabilized in kinase-inactive complexes with p27kip1 or
p21cip1 (Jian et al., 1999; Noya et al., 2001). The analysis
revealed that it was not modulated by treatment with
TNF-a (Fig. 6b).
Cyclin A and PCNA are required for S phase
progression and DNA replication, respectively. After
Fig. 5. Distribution of p27kip1 protein in raft cultures. Immunofluorescence analysis of p27kip1 was carried out on sections from the same raft cultures as those in
Fig. 1. BrdU is revealed by green fluorescence, while p27kip1 is revealed by red fluorescence.
Fig. 6. Cell cycle regulatory proteins in raft cultures in the presence or
absence of TNF-a.Western blots of control (PHK), E7-, or E6/E7, or HPV-18
whole genome containing raft cultures treated as described in Fig. 1. Fifty
micrograms of each of these extracts were blotted for immunodetection of (a)
p21cip1, p27kip1, cyclin A, and PCNA; and (b) p16ink4a and cyclin E.
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in the levels of these two proteins only in the raft cultures
derived from normal PHKs, which are sensitive to this
cytokine. Furthermore, we observed a slight down-regu-
lation of cyclin A in HPV-18 E7 or E6/E7 expressing
cultures. On the other hand, there was no reduction in
PCNA levels in extracts from raft cultures expressing
HPV-18 E7 or E6/E7 genes or those containing the
genomic HPV-18 DNA (Fig. 6a).
p16ink4a inhibits the assembly of cyclin D/cdk4 or cdk6,
which normally regulate pRB function (Gran˜a and Reddy,
1995). The regulation of these kinases by p16ink4a is
bypassed when pRB is inactivated by the oncogenic HPV
E7 protein. Previous reports show that p16ink4a accumulates
in pRB-negative cells such as those expressing high-risk
HPV E7 or in which this factor is inactivated by mutation
(Doki et al., 1997; Kelley et al., 1995; Parry et al., 1995). In
our normal raft cultures, we detected no p16ink4a protein
(Fig. 6b). On the other hand, raft cultures of keratinocytes
containing the complete HPV-18 genome exhibited high
levels of this protein as observed in Western blot assays
E. Boccardo et al. / Virology 328 (2004) 233–243 239using whole cell extracts. TNF-a treatment induced a slight
decrease in p16ink4a levels in raft cultures containing HPV-
18 genome relative to the untreated counterpart.Discussion
TNF-a is a proinflammatory cytokine that plays a key
role in inflammatory and infectious diseases, especially in
viral infections. This cytokine is produced by a wide
variety of cells including activated macrophages, keratino-
cytes, monocytes, lymphocytes, and fibroblasts. It elicits a
broad spectrum of cellular responses including prolifer-
ation, differentiation, and apoptosis (Baud and Karin,
2001). It has been previously shown that HPV-18
immortalized and cervical carcinoma-derived cell lines are
resistant to this cytokine (Vieira et al., 1996; Villa et al.,
1992). In this study, we demonstrated that in organotypic
cultures of primary human keratinocytes, acute transduction
and expression of HPV-18 oncogenes conferred resistance
to growth inhibitory effects of TNF-a. These results
indicate that TNF resistance does not depend on the
acquisition of a fully immortalized or transformed HPV-
associated phenotype.
We show that the basal cells of normal control raft
cultures are highly sensitive to TNF-a. In contrast, raft
cultures containing transfected HPV-18 genome or trans-
duced with E6/E7 oncogene(s) or E7 alone were at least
partially resistant to the inhibitory effect of TNF-a. On the
other hand, transduction of PHKs with retroviruses
containing HPV 18 URR-E6 failed to induce S phase
reentry in suprabasal cells of organotypic cultures as
previously observed (data not shown; Cheng et al., 1995).
However, it was able to partially overcome the inhibitory
effect of TNF-a in the basal cells (our unpublished
observation) where a low level of E6 expression is
expected. Resistance to TNF-a effects mediated by E6
has been previously reported. It has been observed that this
oncoprotein is capable of binding to TNF receptor 1 and
protect mouse fibroblasts, human osteosarcoma cells, and
human histiocyte/monocyte cells from TNF-a-mediated
apoptosis (Filippova et al., 2002). Furthermore, it has been
shown that E6 can down-regulate IL-8 expression in human
keratinocytes by competing with NF-nB/p65 and steroid
receptor co-activator 1 (SRC-1) for binding to the N
terminus and C terminus of the transcriptional activator
CPB, respectively (Huang and McCance, 2002).
The complete genome appeared to be more effective in
conferring TNF-a resistance. There are at least two possible
explanations for this enhanced resistance by cells containing
the whole HPV-18 genomic DNA. First, it could be
attributed to the ability of the intact genome to amplify
and increase the E7 and E6 gene dosage relative to the low
copy number of retrovirus-transduced E7 gene. This
interpretation is in agreement with the observation that
BrdU incorporation in raft cultures derived from PHKsacutely transfected with a replication-defective HPV-16
genome was inhibited by TNF-a, because the nonreplicat-
ing viral DNA was lost during cell division (data not
shown). The second possibility is that viral genes, other than
E6 and E7, also play a role. Currently, we do not know what
cause the HPV-containing raft cultures to become thinner.
There are two possibilities that are not mutually exclusive.
One is that the basal cells, where little E6 or E7 is expressed,
were partially sensitive to TNF-a. The second is that TNF-a
is able to speed up terminal differentiation of the cells in the
upper strata.
Previous reports by Delvenne et al. (1995, 2001) have
shown that TNF-a, alone or in combination with interferon-
g, was able to inhibit the growth of normal and HPV-
transformed keratinocytes in monolayer and organotypic
cultures. The experiments described by these authors differ
from those in the present study in at least two aspects. First,
they describe the effect of TNF-a on organotypic cultures
obtained from HPV-transformed cell lines derived from
cervical carcinomas (SiHa, CasKi, C4-II). Similar results,
using monolayer cultures, were also previously published
by us (Villa et al., 1992; Vieira et al., 1996). In the present
study, we show that acute expression of HPV-18 E7 in early-
passage keratinocytes confers resistance to TNF-a previous
to the onset of a fully immortalized phenotype. This
observation indicates that TNF-a resistance is an early step
in HPV pathogenesis. Second, in the experiments performed
by Delvenne et al. (1995, 2001), TNF-a was present along
the whole organotypic culture duration. As observed by the
authors, this treatment inhibited not only normal keratino-
cytes proliferation but the onset of normal epithelial
stratification. This could be a consequence of early exposure
of keratinocytes to the cytokine. In our study, TNF-a
treatment was reduced to the last 72 h of culture, when
keratinocyte organotypic cultures already display the
morphology of normal epithelium with discrete basal,
spinous, granular, and cornified cell layers.
Among the cell cycle regulatory proteins investigated,
only cyclin A and PCNA that function during S phase are
down-regulated in TNF-a-sensitive cells. However, we do
not know whether this is the cause or the consequence of
growth arrest.
Our results in the raft cultures agree with recent studies
showing that HPV-16 E7 is capable of overcoming the
antiproliferative effect of this cytokine in monolayer
cultures of human keratinocytes (Basile et al., 2001).
However, in that case, the level of p21cip1 protein was
observed to increase by Western blots. In contrast, our
Western blots and in situ investigations did not reveal any
increase in the levels or distribution of the p21cip1 protein
in the normal PHK raft culture, which is sensitive to TNF-
a, nor in raft cultures expressing HPV-18 E7 oncoprotein,
which are at least partialy resistant to this cytokine. The
p21cip1 protein is expressed at or below the sensitivity of
detection in normal raft cultures. Its transcription is up-
regulated in the differentiated keratinocytes but the protein
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basal keratinocytes expressing the E7 gene of HPV 18,
leading to an inhibition of DNA synthesis induced by the
viral oncoprotein (Chien et al., 2002; Jian et al., 1998,
1999; Noya et al., 2001). The stabilization of p21cip1
protein in differentiated keratinocytes expressing HPV-18
E7 is caused by co-stabilization and co-accumulation in a
complex with cdk2 and cyclin E induced by E7. In
agreement, we observed p21cip1 and cyclin E up-regulation
in rafts expressing HPV-18 E7, E6/E7, and HPV genome.
However, TNF-a treatment did not affect the levels and
distribution of p21cip1 along the different cell layers.
Consequently, the level of the co-stabilized cyclin E was
not altered.
Interestingly, the effects of TNF-a on the expression of
p27kip1 appear to depend on the cell type studied. For
example, TNF-a activates the expression of p27kip1 in bone
marrow macrophages (Okahashi et al., 2001). On the other
hand, in the absence of growth factors, TNF-a stimulates
the proliferation of HPV-immortalized keratinocyte cell
lines (Woodworth et al., 1995), and this effect is mediated,
in part, by the decrease of p27kip1 levels (Gaiotti et al.,
2000). The importance of the decrease in levels of the
p27kip1 protein on the pathogenesis by HPV has been
proposed based on studies of cervical cancers (Kim et al.,
2000b; Saito et al., 1999; Skomedal et al., 1999). p27kip1,
unlike p21cip1, is stably expressed during squamous differ-
entiation and continue to increase in the upper strata in
normal raft cultures. In raft cultures that express HPV-18 E7
oncogene, the pattern of p27kip1 distribution was not altered
and high levels of p27kip1 inhibits S phase reentry, because it
sequesters cyclin E/cdk2, as does p21cip1 (Noya et al.,
2001). In the present study, we observed no alteration in the
distribution or level of p27kip1 protein upon treatment with
TNF-a in the control or any of the E7-expressing raft
cultures. Thus, in vivo, decrease in the p27kip1 protein
reported by others appears to be a late event during
evolution of the lesions, rather than a direct effect of the
viral oncogenes.
Cell cycle progression is also regulated by p16ink4a,
which inhibits cdk4 and cdk6 (Gran˜a and Reddy, 1995).
Nakao et al. (1997) described the induction of p16ink4a in
cells immortalized by HPV16 and 18. Furthermore, several
epidemiological studies reported an increase in p16ink4a
levels in cervical cancers, as well as an association of these
alterations with the HPV type present in the lesions (Klaes
et al., 2001; Park et al., 1999; Sano et al., 1998). Moreover,
an association between HPV infection, p16ink4a levels, and
oral carcinomas has also been described (Saito et al., 1999).
Our findings indicate that the induction of p16ink4a
production is an acute response to the introduction of
HPV-18. This is in agreement with observations in lesions
produced by high-risk HPVs (Klaes et al., 2001). Interest-
ingly, we observed a small decrease in the levels of p16ink4a
following treatment with TNF-a. The mechanism by which
TNF-a inhibits the expression of p16ink4a is not known, butthe implications may be important as the ink4 family of
proteins inhibit the activity of NF-nB (Wolff and Naumann,
1999), an important mediator of the antiproliferative effects
of TNF-a in keratinocytes (Chaturvedi et al., 1999; Hu et
al., 2001; Komine et al., 2000; Seitz et al., 2000; Soto et al.,
2000; van Hogerlinden et al., 1999).
In conclusion, our results show that HPV-18 gene
expression confers resistance to TNF-a antiproliferative
effect in raft cultures of acutely transduced primary human
keratinocytes. Furthermore, we describe, for the first time,
that expression of HPV-18 E7 driven from its natural
promoter is sufficient to partially overcome the TNF-a
effect. Moreover, our data indicate that HPV-18-induced
resistance to TNF-a is an early event that takes place in
the absence of a fully immortalized or transformed
phenotype. We are currently examining the individual
contributions of several E7 properties to the establishment
of TNF-a resistance in PHKs. Understanding the HPV
oncogenes-mediated mechanisms that modulate the effects
of this cytokine in epithelial cells could be important in the
control of HPV infection, lesion development, and tumor
progression.Materials and methods
Retroviruses, cells, and organotypic raft cultures
PHKs recovered from neonatal foreskins were grown in
serum-free medium (Life Technologies, Inc., Rockville,
MD), acutely infected with recombinant Moloney murine
leukemia viruses or transfected with HPV 18 whole
genome, and then used to seed the epithelial raft cultures
without extensive passage as previously described (Cheng
et al., 1995; Parker et al., 1997). Recombinant retroviruses
containing HPV-18 URR-E7 or HPV-18 URR-E6/E7 have
been described elsewhere (Cheng et al., 1995). These
vectors express the bacterial neomycin resistance gene
driven by the SV40 promoter, whereas the HPV gene or
genes are under the control of the native HPV regulatory
sequence and promoter (URR for upstream regulatory
region). PHKs harboring the full-length HPV18 genome
were obtained as described previously (Meyers et al.,
1997). Briefly, HPV18 DNA was excised from a pBR322
backbone using EcoRI. Five micrograms of the purified
HPV genome and 500 ng of pEGFP-N1 plasmid that
carries the neomycin-selectable marker were electroporated
into second-passage PHKs. After 24 h, the cells were
selected with 250 Ag/ml of G418 for 3 days. Surviving
cells were amplified and stored in liquid nitrogen until
further use. After 9 days at the medium–air interface, raft
cultures were treated with 2 nM TNF-a (Roche Applied
Science, Indianapolis, IN) for 72 h. BrdU was added at 50
Ag/ml for the last 12 h before harvesting by fixation in
10% buffered formalin, embedded in paraffin, and then cut
into 4-Am sections.
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The primary monoclonal antibodies used for immuno-
blotting (1:1000 dilution in all cases) and in situ immuno-
detections include p16INK4a (554070; Pharmingen, Franklin
Lakes, NJ), p21cip1 (OP64; Oncogene Research, Cambridge,
MA; 1:25), p27kip1 (NCL-p27; Novocastra, Newcastle upon
Tyne, UK; 1:20), and BrdU (18-0103; Zymed Laboratories,
San Francisco, CA.; 1:50).
Protein extraction and immunoblotting
After 12 days at the liquid–air interface, raft cultures
were detached from the collagen matrix with a scalpel and
frozen in liquid nitrogen. Two rafts were minced in a tissue
grinder containing 200 Al of cold lysis buffer (50 mM
HEPES [pH 7], 1 mM DTT, 250 mM NaCl, 4 mM EDTA,
10 mM ZnCl2, 0.5% NP-40) with proteases inhibitors
(Completek, Roche Diagnostics, GR). After 5 min on ice,
the tubes were centrifuged for 20 min at 10000  g and 4
8C to separate the insoluble material. Protein concentrations
were determined by the Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, CA). Fifty micrograms of proteins
were resolved by electrophoresis through sodium dodecyl
sulfate–12% polyacrylamide gels and then transferred to
polyvinylidene difluoride membranes (Amersham Pharma-
cia Biotech, UK) using semidry blotting techniques. The
membranes were blocked for 1 h in 5% nonfat milk, probed
for 1–2 h with the primary antibodies, and, after extensive
washing, reprobed with horseradish peroxidase (HRP)-
conjugated secondary antibodies. The bands were revealed
using enhanced chemiluminescence procedures according to
the manufacturer’s recommendations (Amersham Pharma-
cia Biotech).
Immunohistochemical and immunofluorescence detection
Antigen retrieval was achieved by incubating deparaffi-
nized sections in 10 mM citrate buffer (pH 6) at 95 8C for 10
min. Immunohistochemical detections of BrdU were per-
formed using the primary antibody in conjunction with the
Histostain-SP broad-spectrum kit following the manufactur-
er’s instructions (Zymed Laboratories). The sections were
then counterstained with hematoxylin. Images were cap-
tured with a SPOT digital camera (Diagnostic Instruments,
Sterling Heights, MI) attached to an Olympus BH-2
microscope. For double immunofluorescence involving
BrdU, the sections were treated for antigen retrieval,
blocked, and then probed overnight with the monoclonal
antibody to the protein antigen of interest (anti-p21cip1 Ab-
1, Oncogene Research; anti-p27kip1 NCL-27, Novocastra).
The sections were then washed with phosphate-buffered
saline and reprobed with biotinylated anti-mouse immuno-
globulin G (IgG). After washing, the sections were reacted
with streptavidin–Texas Red (1:50, Vector Laboratories,
Burlingame, CA), and probed with fluorescein-conjugatedanti-BrdU antibody (1:50, Roche Biochemicals, GR). The
images were captured with an Olympix 2000 digital camera
(Life Sciences Resources, Cambridge, UK) attached to an
Olympus Provis AX70 microscope. All images were
digitally processed using Photoshop 6.0 (Adobe Systems,
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